ELVINETTE® - Bioequivalent to Yasminelle®

  • Contains 0.02mg ethinylestradiol and 3mg drospirenone, exactly the same active ingredients as Yasminelle®¹-²

 

  • Indicated for the prevention of pregnancy in women who elect to use an oral contraceptive¹

 

  • Inhibits ovulation & causes changes in the endometrium¹

 

  • Contains drospirenone which exhibits both antiandrogenic & antimineralocorticoid properties¹

 

  • Drospirenone has a pharmacological profile resembling the natural hormone progesterone¹

 

  • Is highly effective when taken correctly & consistently¹-⁴

 

  • ELVINETTE has a Pearl Index of 0.31¹

 

  • Contains Soya lecithin -  Patients with allergies to soya or peanut should not be prescribed ELVINETTE™1

 

  • ELVINETTE is non GMS reimbursed

 

ELVINETTE  is suitable for use in the following patient groups:⁵-⁶

  • Women who want autonomy and control over their menstrual cycle
  • Women aged up to 50 years with no other medical conditions
  • Women with a BMI of ≤34kg/m² who do not smoke 
  • Women ≥6 months postpartum if fully breast feeding
  • Women ≥6 weeks postpartum if not breast feeding
  • Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
  • Women with endometriosis

 

 

 

 

References:
1. Elvinette® SmPC
2. Yasminelle® SmPC
    available at www.medicines.ie
3. MIMS Ireland (August 2017) 'Contraception' MPI Media Ltd, Dublin.
4. Krattenmacher, R. 2000 Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38.
   (Updated January 2007) London: FSRH, 2007.
5. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update.
6. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016